evidence table
Coenzyme Q10 Blood Pressure Meta-Analysis Evidence Table
Structured evidence table for Coenzyme Q10 Blood Pressure Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Coenzyme Q10 Blood Pressure Meta-Analysis | Importantly, while elevated intraocular pressure (IOP) is a well-established risk factor and the only available treatment target, it is neither necessary nor sufficient for the development of glaucoma, as evidenced by the existence of normal-tension glaucoma and the observation that many patients continue to progress despite achieving target IOP levels. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Coenzyme Q10 Blood Pressure Meta-Analysis | It is estimated that the number of individuals affected by glaucoma will continue to rise, with substantial socioeconomic impact due to vision loss and associated disability.Age is the most prominent risk factor, but genetic predisposition, vascular dysregulation, and systemic metabolic dysfunction have also been implicated in disease susceptibility and progression. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Coenzyme Q10 Blood Pressure Meta-Analysis | Studies suggest that up to 28% of retinal ganglion cells may be lost before early visual field defects become apparent.Advances in imaging, home-based visual field monitoring, and artificial intelligence-assisted analysis are being developed to improve early detection and risk stratification, but challenges remain in predicting individual disease trajectories. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Coenzyme Q10 Blood Pressure Meta-Analysis | 1 2 , Glaucoma is a common neurodegenerative disease characterized by the degeneration of retinal ganglion cells and their axons, leading to characteristic structural changes at the optic nerve head and corresponding visual field loss. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Coenzyme Q10 Blood Pressure Meta-Analysis | Despite major advancements in pharmacotherapies and interventional cardiology, substantial residual risk persists among patients with established disease (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Blood Pressure Meta-Analysis | Additionally, many nutraceuticals are perceived to possess favorable safety and tolerability profiles compared to conventional medications, making them attractive for long-term risk reduction (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Blood Pressure Meta-Analysis | Banach et al., 2018 Cicero et al., 2017 Sesso et al., 2008 However, the field is marked by heterogeneous and sometimes contradictory evidence. | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
| Coenzyme Q10 Blood Pressure Meta-Analysis | Roth et al., 2020 Ganda et al., 2018 Visseren et al., 2021 Cardiovascular disease (CVD) is the leading cause of mortality worldwide, accounting for nearly one-third of global deaths each year (). | 3 | Wu Xun (2026) | Advances in cardiovascular supplementation: mechanisms, efficacy, and clinical perspectives |
Source documents